Clinical Study

Nrg-Lu005- Limited Stage Small Cell Lung Cancer (Ls-Sclc): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Posted Date: Feb 5, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Radiation Oncology
  • Type of Study: Drug

The purpose of this study is to compare progression free survival (PFS) and overall survival for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab.

Criteria:

Proven Diagnosis Of Limited Stage Small Cell Lung Cancer, Measurable Disease Prior To Chemo, Age = 18, Ecog 0-2, No Prior Malignancy Within 2 Yrs, No Prior Rt To Lungs Or Mediastinum

Keywords:

Lung, Sclc

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.